Phathom PharmaceuticalsPHAT +1.61%23 3-Year ROIIC % is 18.60 as of Dec. 2025. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,320 Biotechnology companies, Phathom Pharmaceuticals ranks better than 64.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Phathom Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 18.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Phathom Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
PHAT's 3-Year ROIIC % is ranked better than 64.55% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs PHAT: 18.60
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Phathom Pharmaceuticals 3-Year ROIIC % Related Terms
Phathom Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAT vs GERN, ODTX, SPRY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Phathom Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phathom Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's 3-Year ROIIC % falls into.
Phathom Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -159.986 (Dec. 2025) - -172.44 (Dec. 2022) )
/
( 80.415 (Dec. 2025) - 13.453 (Dec. 2022) )
=
12.454
/
66.962
=
18.60%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Phathom Pharmaceuticals (PHAT) has a 3-Year ROIIC % of 18.60 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Phathom Pharmaceuticals and its competitors. According to the industry distribution chart, Phathom Pharmaceuticals ranks #468 out of 1320 companies in the Biotechnology industry, placing it in the top 35.5%.
Is Phathom Pharmaceuticals' 3-Year ROIIC % too high?
Phathom Pharmaceuticals' current 3-Year ROIIC % is 18.60. Based on the distribution chart, Phathom Pharmaceuticals ranks #468 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' 3-Year ROIIC % compare to GERN and ODTX?
According to the Biotechnology industry distribution chart, Phathom Pharmaceuticals ranks #468 out of 1320 companies for 3-Year ROIIC %. This puts Phathom Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current 3-Year ROIIC % is 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current 3-Year ROIIC % of 18.60. The current 3-Year ROIIC % is 18.60. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current 3-Year ROIIC % is 18.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score
Get the complete analysis for PHAT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAT has been successfully added to your 
